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Abstract
Background: Amylin is the most abundant component of islet amyloid implicated in the development of type 2 diabetes.
Plasma amylin levels are elevated in individuals with obesity and insulin resistance. Monocyte chemoattractant protein-1
(MCP-1, CCL2) is involved in insulin resistance of obesity and type 2 diabetes. We investigated the effect of MCP-1 on amylin
expression and the underlying mechanisms with murine pancreatic b-cell line MIN6 and pancreatic islets.
Methodology/Principal Findings: We found that MCP-1 induced amylin expression at transcriptional level and increased
proamylin and intermediate forms of amylin at protein level in MIN6 cells and islets. However, MCP-1 had no effect on the
expressions of proinsulin 1 and 2, as well as prohormone convertase (PC) 1/3 and PC2, suggesting that MCP-1 specifically
induces amylin expression in b-cells. Mechanistic studies showed that although there is no detectable CCR2 mRNA in MIN6
cells and islets, pretreatment of MIN6 cells with pertussis toxin inhibited MCP-1 induced amylin expression, suggesting that
alternative Gi-coupled receptor(s) mediates the inductive effect of MCP-1. MCP-1 rapidly induced ERK1/2 and JNK
phosphorylation. Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced
amylin mRNA expression. MCP-1 failed to induce amylin expression in pancreatic islets isolated from Fos knockout mice.
EMSA showed that JNK and ERK1/2 were involved in MCP-1-induced AP1 activation. These results suggest that MCP-1
induces murine amylin expression through AP1 activation mediated by ERK1/2 or JNK. Further studies showed that
treatment of MIN6 cells with NF-kB inhibitor or overexpression of IkBa dominant-negative construct in MIN6 cells
significantly inhibited MCP-1-induced amylin expression, suggesting that NF-kB related signaling also participates in MCP-1-
induced murine amylin expression.
Conclusions/Significance: MCP-1 induces amylin expression through ERK1/2/JNK-AP1 and NF-kB related signaling
pathways independent of CCR2. Amylin upregulation by MCP-1 may contribute to elevation of plasma amylin in obesity and
insulin resistance.
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Introduction
Islet amyloid deposition is a characteristic pathologic feature of
the pancreas in type 2 diabetes patients [1]. Amylin is the major
component of islet amyloid deposition [2,3]. It has been reported
that the formation of pancreatic islet amyloid deposits correlates
with loss of b cell mass and progressive decline of insulin secretion,
suggesting a close relationship between islet amyloid deposition
and the development of type 2 diabetes [1]. Amylin is mainly
expressed and secreted by pancreatic b cells. Animal and human
studies suggest that increased production and secretion of amylin
might contribute to accumulation and aggregation of islet amyloid
in pancreas. Transgenic rats with b cell overexpression of human
amylin develop islet amyloid deposits which are associated with b
cell death and development of hyperglycemia [4]. Therefore, to
elucidate the mechanisms controlling amylin gene expression
in pancreatic b cells may provide a better understanding of b cell
gene expression and the pathogenesis of type 2 diabetes.
Amylin gene expression has been reported to be regulated by
glucose, free fatty acids and forskolin [5–7]. Glucose stimulates
amylin expression and secretion in a Ca
2+ and PDX-1 dependent
manner [5]. Our previous study demonstrated that Ca
2+-PKC
signaling pathways and de novo synthesized protein(s) are involved
in free fatty acid-induced amylin expression [7]. Plasma amylin
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19559levels have been reported to be elevated under pathological
conditions which contribute to the development of type 2 diabetes.
Elevated circulating levels of amylin have been detected in obese
subjects, insulin resistance and type 2 diabetes patients [8–11].
Pancreatic amylin mRNA and plasma amylin levels are also
elevated in genetically obese, insulin-resistant rats [12]. However,
the underlying mechanisms are not clear.
Obesity and insulin resistance are characterized by a chronic,
systemic low-grade state of inflammation. Biomarkers of inflamma-
tion, such as TNF-a, interleukin (IL)-6, monocyte chemoattractant
protein-1 (MCP-1, CCL2), and C-reactive protein, are increased in
obesity, associated with insulin resistance, and predict the
development of type 2 diabetes [13–16]. Circulating TNF-a and
MCP-1 are increased in obesity and have been implicated as
causative factors in obesity-associated insulin resistance and the
development of type 2 diabetes [13,17–20]. We recently find that
TNF-a can upregulate amylin expression in pancreatic b cells [21].
In the present study, we used murine pancreatic b cell line MIN6
and pancreatic islets to examine the effect of MCP-1 on amylin
expression, and further explore the underlying mechanisms.
Results
MCP-1 induces murine amylin expression
To determine the effect of MCP-1 on amylin gene expression,
murine pancreatic b cell line MIN6 was challenged with different
concentrations of MCP-1 for different lengths of time, and the
mRNA levels of amylin were detected by quantitative real-time
PCR. As shown in Figures 1A and 1B, MIN6 cells cultured in
DMEM containing 5.6 mM glucose expressed transcripts for
amylin, which was significantly enhanced by MCP-1 stimulation.
The minimal concentration of MCP-1 to significantly induce
amylin gene expression was obtained at 116 pM with a 9 h
incubation period. Consistent with the results obtained from
MIN6 cells, mRNA level of amylin in murine pancreatic islets was
significantly enhanced by MCP-1 after 9 h of stimulation
(Figure 1C). Interestingly, the inductive effect of MCP-1 on
amylin mRNA is more potent in islets than in MIN6 cells,
suggesting that amylin expression in response to MCP-1 is more
sensitive in islets than in transformed b cells. As amylin and insulin
are co-localized in b cells and co-secreted in response to glu-
cose [22], we then examined the effect of MCP-1 on proinsulin
expression in MIN6 cells. While MCP-1 upregulated amylin
mRNA levels in MIN6 cells and murine primary islets in a time-
dependent manner (Figure 1A), it had no effect on proinsulin 1
and proinsulin 2 mRNA levels in MIN6 cells (Figure 1D),
suggesting that MCP-1 specifically induces amylin expression in b
cells.
To determine whether MCP-1-induced increase of amylin
mRNA level was due to the increase of amylin mRNA stability,
MIN6 cells pretreated with or without 11.6 nM MCP-1 for 9 h
were cultured with 5 mg/ml actinomycin D for 2, 5, 7 h, then
Figure 1. MCP-1 upregulates amylin gene expression. MIN6 cells were incubated with 11.6 nM MCP-1 for different time periods (A, D), or with
different concentrations of MCP-1 for 9 h (B), then total RNA was extracted and examined for amylin (A, B) or proinsulin (D) mRNA level by real-time
PCR. C. Mouse pancreatic islets were treated with 11.6 nM MCP-1 for 9 h, amylin mRNA level was examined by real-time PCR. E. MIN6 cells pretreated
with or without 11.6 nM MCP-1 for 9 h were cultured with 5 mg/ml actinomycin D for the indicated time intervals. Amylin mRNA levels were then
examined by real-time PCR. *p,0.05 vs. MIN6 cells or pancreatic islets cultured with control medium. All data are shown as mean6SD of three
independent experiments.
doi:10.1371/journal.pone.0019559.g001
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MCP-1 markedly increased amylin mRNA level, there was no
significant difference in the curves of mRNA decay between MCP-
1 treated and control groups (Figure 1E), suggesting that MCP-1
increase amylin expression at transcriptional level.
We next examined the effect of MCP-1 on amylin protein
expression. Western blot assay showed that under resting state,
mature amylin is the main form of amylin in murine pancreatic
islets. Stimulation of murine islets with 11.6 nM MCP-1 or
16 mM glucose for 24 h, all significantly increased the levels of
proamylin (,8 kDa) and the intermediate form (,6 kDa) of
amylin (Figure 2A and 2B). MCP-1 had no significant effect on
expressions of prohormone convertase (PC) 1/3 or PC2
(Figure 2C), which are responsible for proamylin processing
[23]. These results might explain the increase of proamylin and
the intermediate form of amylin by MCP-1 stimulation.
CCR2 is not involved in MCP-1-induced amylin gene
expression
As CCR2, a Gi-coupled receptor, is the only known receptor
that functions at physiologic concentrations of MCP-1. We
examined if MCP-1 induces amylin expression through CCR2.
Surprisingly, CCR2 mRNA was not detectable in both MIN6 cells
and murine islets, and treatment of MIN6 cells with 11.6 nM
MCP-1 for up to 9 hours had no effect on CCR2 expres-
sion (Figure 3A). However, the induction of amylin by MCP-1 was
inhibited by pretreatment of the cells with pertussis toxin
(Figure 3B), suggesting that alternative Gi-coupled receptor(s)
mediates the inductive effect of MCP-1.
AP1 activation by ERK1/2 or JNK is involved in
MCP-1-induced amylin gene expression
It has been reported that MCP-1 activates extracellular signal-
regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK)
MAPK in endothelial cells and monocytes/macrophages [24–26].
So we tested if MAPK activation was involved in MCP-1-induced
amylin gene expression. As shown in Figures 4A and 4B, treatment
of MIN6 cells with 11.6 nM MCP-1 stimulated rapid phosphor-
ylation of ERK1/2 and JNK. Pretreatment of MIN6 cells with
PD98059 (MEK1/2 inhibitor) and SP600125 (JNK II inhibitor)
significantly inhibited MCP-1-induced ERK1/2 and JNK phos-
phorylation, respectively. We observed that pretreatment of MIN6
cells with PD98059 and SP600125 both significantly inhibited
MCP-1-induced amylin gene expression (Figure 4C). PD98059
and SP600125 at tested concentrations had no effect on cell
viability as examined by MTT assay (data not shown). These
Figure 2. MCP-1 induces amylin protein expression. A. Murine pancreatic islets were cultured in control medium containing 2.8 mM glucose
overnight followed by treatment with 11.6 nM MCP-1 or 16 mM glucose for 24 h. Amylin protein expression was examined by Western blot assay. A
representative gel is shown, in which synthetic rat amylin was used as amylin positive control. B. Quantification of Western blot (A). *p,0.05 vs
proamylin in islets cultured with control medium,
#p,0.05 vs intermediate form of amylin in islets cultured with control medium. Mean6SD of three
independent experiments. C. MIN6 cells were incubated with 11.6 nM MCP-1 for different time periods, then total RNA was extracted and examined
for prohormone convertase (PC)1/3 and PC2 mRNA levels by real-time PCR. All data are shown as mean6SD of three independent experiments.
doi:10.1371/journal.pone.0019559.g002
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through activation of ERK1/2 and JNK related signaling
pathways.
Transcription factor activator protein-1 (AP1) has been reported
to mediate MCP-1 induced inflammatory activation of human
tubular epithelial cells and smooth muscle cell proliferation
[27,28]. When we analyzed murine amylin gene with AliBaba
2.1 program (http://wwwiti.cs.uni-magdeburg.de/grabe/ali-
baba2.), several AP1 binding sites were revealed to exist in the
promoter region. To examine whether AP1 is involved in MCP-1-
induced amylin gene expression, we pretreated MIN6 cells with
curcumin, an inhibitor of AP1 [29], and then we challenged these
cells with 11.6 nM MCP-1. We found that curcumin significantly
inhibited amylin mRNA upregulstion by MCP-1 (Figure 5A),
indicating AP1 is involved in MCP-1-induced amylin gene
expression. Curcumin at tested concentration had no effect on
cell viability as examined by MTT assay (data not shown). As
curcumin has been reported to regulate various molecules [30],
the possibility of the involvement of other curcumin targets in
amylin upregulation by MCP-1 can not be ruled out. Fos protein is
a component of AP1 which is a dimeric protein complex [31]. We
further examined the effect of MCP-1 on amylin expression in
pancreatic islets isolated from Fos knockout mice and got negative
results (Figure 5B). These results confirm that AP1 plays an
essential role in the induction of amylin gene expression by MCP-
1.
ERK and JNK have been reported to be upstream molecules of
AP1 [31]. We then tested if MCP-1 activates AP1 through ERK
1/2 and JNK in pancreatic b cells. EMSA assay with a consensus
AP1 probe (C-AP1), or an amylin AP-1 probe (A-AP1) which
contains the AP1 binding sequence at the promoter region
(-1574/-1568) of murine amylin gene, showed that MCP-1
significantly increased the binding activity of AP1 in MIN6 cells
(Figure 6A, B). In MCP-1-stimulated cells, both excess unlabeled
C-AP1 probe and A-AP1 probe could compete for amylin AP1
binding, and excess cold C-AP1 could compete for consensus AP1
binding (Figure 6A), suggesting that the A-AP1 probe is specific,
and MCP-1 induced AP1 binding to the promoter region of
amylin gene. The increased amylin AP-1 activity induced by
MCP-1 was significantly inhibited by pretreatment of MIN6 cells
with JNK inhibitor SP600125, or MEK1/2 inhibitor PD98059
(Figure 6B, C). Taken together, these results suggest that MCP-1
induces amylin gene expression in b cells through ERK1/2-AP1
and JNK-AP1 pathways.
Figure 4. ERK1/2 and JNK signaling pathways are involved in
MCP-1-induced amylin gene expression. A–B. MIN6 cells pre-
treated with 30 mM PD98059 (PD) or 50 mM SP600125 (SP) for 2 h were
stimulated with 11.6 nM MCP-1 for 5 min. ERK1/2 or JNK phosphory-
lation was examined by Western blot. The experiments were performed
at least three times and representative results are shown. C. MIN6 cells
were incubated with control medium (CM), 30 mM PD98059 (PD) or
50 mM SP600125 (SP) for 1 h, then stimulated with 11.6 nM MCP-1 for
9 h and examined for amylin expression by real-time PCR. *p,0.05 vs
cells cultured with CM.
#p,0.05 compared with cells treated with MCP-
1 alone. Mean6SD of three independent experiments.
doi:10.1371/journal.pone.0019559.g004
Figure 3. MCP-1 induces amylin gene expression independent
of CCR2. A. CCR2 mRNA levels in MIN6 cells treated with 11.6 nM
MCP-1 for different periods of time, or unstimulated islets was
examined by RT-PCR. CCR2 expression in murine microglia cell line
N9 was shown as positive control. NC: negative control without cDNA
template. B. MIN6 cells were incubated with control medium (CM) or
0.5 mg/ml pertussis toxin (PTX) for 1 h, then stimulated with 11.6 nM
MCP-1 for 9 h and examined for amylin expression by real-time PCR.
*p,0.05 vs cells cultured with CM.
#p,0.05 compared with cells
treated with MCP-1 alone. Mean6SD of three independent
experiments.
doi:10.1371/journal.pone.0019559.g003
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related pathways
Transcription factor nuclear factor-kB (NF-kB) is another
signaling molecule involved cell activation by MCP-1 [27,28].
Thus we checked if NF-kB was involved in MCP-1 -induced
amylin gene expression in pancreatic b cells. Pretreatment of
MIN6 cells with sulfasalazine (NF-kB inhibitor) [32] significantly
inhibited MCP-1-induced amylin gene expression (Figure 7A). As
sulfasalazine at tested concentrations had no effect on cell viability
(data not shown), these results suggest that NF-kB is involved in
amylin upregulation by MCP-1. To further confirm that NF-kB
activation is involved in the induction of amylin expression by
MCP-1, we transfected MIN6 cells with an IkBa dominant-
negative construct (IkBa-DN) containing a S32A and S36A
substitutions [33] or control vector flag-zeo. Overexpression of
IkBa-DN in MIN6 cells (Figure 7B) significantly attenuated MCP-
1-induced amylin gene expression, suggesting an essential role of
NF-kB in the upregulation of amylin expression by MCP-1.
Discussion
In the current study, we studied the effect of MCP-1 on amylin
gene expression in both mouse pancreatic b cell line MIN6 and
pancreatic islets. We found that MCP-1 upregulated amylin
mRNA and protein levels but had no effect on amylin mRNA
stability. We further demonstrated that MCP-1 induced amylin
gene expression through ERK1/2/JNK-AP1 pathways and NF-
kB related signaling pathways which are independent of CCR2.
Islet amyloid is a pathological hallmark of the pancreatic islet
present in a substantial proportion of individuals from all ethnic
groups with type 2 diabetes [34–36]. Studies in spontaneous islet
amyloid formation in macaques and domestic cats have shown
that amyloid forms in islets before fasting hyperglycemia, and the
extent of amyloid deposition is associated with both loss of b cell
mass and impairment in insulin secretion and glucose metabolism,
suggesting a causative role for islet amyloid in the islet lesion of
type 2 diabetes [37]. Mechanistic studies have demonstrated that
amylin can inhibit b cell insulin secretion [38], induce b cell
apoptosis [37,39,40], and cause insulin resistance [41,42] in both
in vitro and in vivo systems. In addition, prefibrillar assemblies of
human amylin can bind and disrupt lipid bilayers and form ion-
permeable pores, leading to destabilization of the intracellular
ionic environment [43,44]. Therefore, elucidation of the mecha-
nisms involved in amylin expression and deposition will not only
contribute to the understanding of the pathogenesis of type 2
diabetes but also provide novel strategies for the treatment and
prevention of this disease.
Insulin resistance is an important contributor to the pathogen-
esis of type 2 diabetes, and obesity is a risk factor for its
development. Recent data have revealed that the plasma con-
centrations of inflammatory mediators, such as TNF-a, MCP-1
and IL-6, are increased in the insulin resistant states of obesity
[13]. Increased circulating levels of MCP-1 and amylin have been
detected in obese and type 2 diabetes patients [8–11,14,15,45,46].
High MCP-1 levels contribute to diabetes risk independently of
previously-described clinical, metabolic and immunological risk
factors [16]. In vitro studies showed that MCP-1 could directly
induce insulin resistance in adipocytes and skeletal muscle cells
[47,48]. Animal studies have demonstrated that increase of MCP-
1 expression in adipose tissue contributes to the macrophage
infiltration into this tissue and insulin resistance [49,50], while
systemic elevation of MCP-1 is sufficient to induce systemic insulin
resistance irrespective of adipose tissue inflammation [51]. Our
results demonstrated that MCP-1 induced amylin expression in
pancreatic b cells at both mRNA and protein levels, indicating
that in addition to directly induce insulin resistance, MCP-1 may
indirectly contribute to insulin resistance by upregulating amylin
expression. The upregulation of amylin gene expression by MCP-1
may be an important link between chronic inflammation and
insulin resistance.
Our studies showed that MCP-1 induced murine amylin
expression in MIN6 cells and pancreatic islets at transcription
level. The inductive effect of MCP-1 is more potent in islets than
in MIN6 cells. As MIN6 cells and murine islets don’t express
MCP-1 receptor CCR2 but the induction of amylin by MCP-1
can be blocked by pertussis toxin, the inductive effect of MCP-1
may be mediated through other Gi-coupled receptor(s) than
CCR2. Supporting our results, other researchers also reported the
absence of detectable CCR2 mRNA in murine b-cell line and
islets [52]. MCP-1 has been reported to induce cell responses of
mouse astrocytes and human aortic smooth muscles with no
detectable CCR2 [53,54], and to induce the expression of tissue
factor in aortic smooth muscles isolated from CCR2 knockout
mice through alternative Gi-coupled receptor(s) [55]. By using a
series of biochemical and molecular biology methods with specific
inhibitors for MAP kinases, AP1, NF-kB, dominant-negative
constructs for IkBa, and islets from Fos-/- mice, we demonstrated
that MCP-1 induced amylin expression in murine pancreatic b
cells through JNK/ERK1/2-AP1 and NF-kB pathways. AliBaba2
program analysis revealed that there are only AP1 binding sites
but not NF-kB binding sites existing in the promoter region of
mouse amylin gene. Therefore, NF-kB activation may play an
indirect role in murine amylin upregulation by MCP-1.
Amylin is synthesized in b cells as a precursor molecule,
proamylin. Production of mature amylin from proamylin is a two-
step process, initiated predominantly by cleavage at its COOH
terminus by the prohormone convertase (PC)1/3, followed by
cleavage of the resulting NH2-terminally extended intermediate
by PC2 [23]. Our studies showed that MCP-1 increased
Figure 5. MCP-1 stimulates amylin gene expression through
activation of AP1. A. MIN6 cells pretreated with control medium (CM)
or 10 mM curcumin (Cur) for 1 h were stimulated with 11.6 nM MCP-1
for 9 h, then amylin mRNA levels were examined by real-time PCR.
*p,0.05 vs cells cultured with control medium.
#p,0.05 compared
with cells treated with MCP-1 alone. B. Mouse pancreatic islets isolated
from wild type (WT) or Fos -/- mice were treated with 11.6 nM MCP-1 for
9 h, amylin mRNA level was examined by real-time PCR. *p,0.05 vs.
islets from WT mice cultured with control medium.
#p,0.05 vs. islets
from WT mice in response to MCP-1. All data are shown as mean6SD of
three independent experiments.
doi:10.1371/journal.pone.0019559.g005
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We found that MCP-1 stimulated amylin expression but had no
significant effect on PC1/3 and PC2 expression, which may lead
to the upregulation of proamylin and the intermediate form of
amylin but not the mature form of amylin. In addition to mature
amylin, NH2-terminally extended proamylin is also a component
of islet amyloid [56]. It has been proposed that defects in the
processing, sorting, and/or secretion of proamylin by b cells may
initiate amyloid formation [1,57–59]. Amylin precursor upregula-
tion by MCP-1 may contribute to amylin elevation and amyloid
formation. Pancreatic amyloid is found in humans but not in
rodents. This has been attributed to the amino acids in some
regions of human amylin which are easy to form aggregate [60].
Both human and rodent amylin are secreted in response to
glucose, free fatty acids and food intake [5,7]. Whether the amylin
secretion pathway in human and rodent are different upon MCP-1
stimulation or under pathological conditions, and the effects of
MCP-1 on human proamylin processing and amylin deposition
need further investigation.
Taken together, our studies demonstrate that MCP-1 induces
amylin gene expression in murine b cells through JNK/ERK1/2-
AP 1 and NF-kB related signaling pathways. Our results and
available evidence suggest that in addition to direct involvement in
insulin resistance, MCP-1 may play an important role in
overexpression of amylin in obesity and insulin resistance which
are causally linked to the development of type 2 diabetes.
Materials and Methods
Materials
MCP-1 was purchased from Peprotech Inc. (Rocky Hill, NJ,
USA). Pertussis toxin, PD98059, SP600125, sulfasalazine, and
curcumine were from Calbiochem (La Jolla, CA, USA). Type V
collagenase was from Sigma Aldrich (Louis, MO, USA). Ficoll 400
was purchased from Amersham Pharmacia Biotech (Piscataway,
NJ, USA). DMEM was from Gibco BRL (Burlington, Ontario,
Canada). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA,
USA). Unless otherwise stated, all other reagents were purchased
from Sigma Aldrich.
Pancreatic islet preparation and cell culture
Pancreatic islets were isolated from C57/BL6 mice (from
Shanghai SLAC Laboratory Animal Company, China) or Fos
knockout mice [61] by type V collagenase digestion followed by
Ficoll 400 gradient separation, as described previously [62]. Islets
were cultured in DMEM containing 5.6 mM glucose, 10% FBS,
100 U/ml penicillin and 100 g/ml streptomycin. Batches of 100
and 250 islets were used for RNA extraction and Western blot
assay, respectively. All experiments using animals were in
accordance with the ‘Principles of laboratory animal care’ (NIH
publication no. 85–23, revised 1985; http://grants1.nih.gov/
grants/olaw/references/phspol.htm), and were approved by the
Institutional Animal Care and Use Committee, Institute for
Nutritional Sciences, Chinese Academy of Sciences (Permit No.
2009-AN-01). MIN6 cells, a mouse pancreatic b cell line, were
cultured in DMEM containing 5.6 mM glucose, 10% FBS, and
Figure 6. MCP-1 activates AP1 through ERK1/2 and JNK. A.
MIN6 cells were treated with or without 11.6 nM MCP-1 for 2 h, the
nuclear protein was extracted and applied for EMSA using biotin-
labeled amylin AP1 probe (Bio-A-AP1 probe) or consensus AP1 probe
(Bio-C-AP1 probe). 100-fold of unlabeled consensus AP1 probe (cold-C-
AP1) or amylin AP1 probe (cold-A-AP1) was used as competitor. The
experiments were performed at least three times and representative
results are shown. B. MIN6 cells pretreated with 50 mM SP600125 (SP) or
30 mM PD98059 (PD) for 1 h were stimulated with 11.6 nM MCP-1 for
another 2 h. The nuclear protein was extracted and applied for EMSA
using biotin-labeled amylin AP1 probe. *p,0.05 vs cells cultured with
control medium.
#p,0.05 compared with cells treated with 11.6 nmol/l
MCP-1 alone. Mean6SD of three independent experiments. C. A
representative gel of B is shown.
doi:10.1371/journal.pone.0019559.g006
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RNA extraction, PCR and real-time PCR
Total RNA was extracted from MIN6 cells or mouse pancreatic
islets using the Trizol reagent (Invitrogen, Carlsbad, CA, USA)
and depleted of contaminating DNA with RNase-free DNase
according to manufactures’ instructions. cDNA was synthesized
from 2 mg RNA with M-MuLV reverse transcriptase and random
hexamer according to manufacturer’s instructions (Fermentas,
Burlington, Ontario, Canada). Reverse-transcribed cDNA in
triplicate samples were checked for target mRNA level by PCR
or quantitative real-time PCR with Power SYBR Green PCR
master Mix (Applied Biosystems Inc, Warrington WAI4SR, UK)
on ABI Prism 7500 sequence detector (Applied Biosystems Inc,
Foster City, CA, USA). Primers used in the experiment were:
murien CCR2: 59-ATAAGGGCTCTTGTTTGATCTTTFCC
(sense), 59-TGGCTATTCCATATACACCTTTCCC (antisense)
[63]; murine amylin: 59-CAGCTGTCCTCCTCATCCTC
(sense), 59-GCACTTCCGTTTGTCCATCT (antisense); murine
b-actin: 59-CAACGAGCGGTTCCGAT (sense); 59-GCCACAG-
GATTCCATACCCA (antisense); murine proinsulin 1: 59-TCTT-
CTACACACCCAAGTCCCG (sense), 59-CTCCAACGCCAA-
GGTCTGAA (antisense); murine proinsulin 2: 59-CTTCT-
TCTACACACCCATGTCCC (sense), 59-CCAAGGTCTGAA-
GGTCACCTG (antisense); murine prohormone convertase (PC)
1/3: 59- ACATGGGGAGAGAATCCTGTAGGCA (sense), 59-
CATGGCCTTTGAAGGAGTTCCTTGT (antisense); murine
PC2: 59- TTGATGCAGGTGCCATGGTGAA (sense), 59-AC-
TTGTCAAAGCCCACCTTGGAGT (antisense). Amplification
of the target cDNA was normalized to b-actin expression. Relative





Phosphorylation of ERK1/2 or JNK was examined as described
previously [64]. Briefly, MIN6 cells were stabilized in KRB buffer
for 2 h followed by stimulation with MCP-1 for 5 min. The cells
were then lysed with cold RIPA lysis buffer containing 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 100 mM Tris
(pH 8.0), 10 mM NaF, 1% deoxycholic acid, 1 mM PMSF, 1 mM
sodium vanadate, 1 mM DTT, 10 mM Aprotinin and 4 mM
leupeptin. The cell lysates were centrifuged at 12,000 rpm for
20 min to remove insoluble materials, and the concentration of
protein was determined by Bradford assay. Protein were
electrophoresed on 10% SDS-PAGE gel, transferred onto
polyvinylidene difluoride (PVDF) membrane (Millipore Corpora-
tion, Bedford, MA) and probed with antibodies against phosphor-
ylated ERK1/2 (Santa Cruz Biotechnology, CA) or JNK (Cell
Signaling Technology, Beverly, MA), followed by incubation with
a horseradish peroxidase-conjugated secondary antibody. Immu-
noreactive bands were detected by Supersignal West Pico
chemiluminescent substrate (Pierce, Rockford, IL, USA) and X-
Omat BT film (Eastman Kodak Company, Rochester, New York,
USA). The membranes were stripped and re-probed with antibody
against ERK1/2 or JNK (Cell Signaling Technology, Beverly,
MA) to ensure equal loading.
To examine the expression of amylin proteinby murine islets, islet
proteins (10–15 mg) were electrophoresed on a 15% polyacrylamide
gel using Tris-tricine buffer [7], transferred onto PVDF membrane,
and probed with anti-rat amylin antiserum (T-4145, Peninsula
Laboratory, Belmont, CA, USA), or anti-b-actin monoclonal
antibody (Sigma Aldrich, Louis, MO, USA), followed by incubation
with a horseradish peroxidase-conjugated secondary antibody.
Transient transfection
MIN6 cells were transfected with dominant-negative plasmid or
control vector using SuperFect Transfection Reagent (Qiagen,
Valencia, CA) according to the manufacture’s instruction. Thirty-
six hours after transfection, the cells were stimulated with MCP-1
for 9 hours, and amylin mRNA expression was then detected by
real-time PCR. IkBa-DN, a dominant-negative IkBa expressing
plasmid, and its control vector flag-zeo were a kind gift from Dr.
R. Lin (McGill University, Montreal, Canada).
Figure 7. Involvement of NF-kB signaling pathway in MCP-1-induced amylin gene expression. A. MIN6 cells pretreated with control
medium or different concentrations of sulfasalazine for 1 h were stimulated with 11.6 nM MCP-1 for 9 h, then amylin mRNA levels were examined by
real-time PCR. *p,0.05 vs cells cultured with control medium.
#p,0.05 compared with cells treated with MCP-1 alone. B. MIN6 cells transiently
transfected with IkBa dominant-negative construct (IkBa-DN) or control vector flag-zeo for 36 h were treated with control medium or 11.6 nM MCP-1
for another 9 h, amylin mRNA levels were examined by real-time PCR. *p,0.05 vs. flag-zeo-transfected cells cultured with control medium.
#p,0.05 vs. flag-zeo-transfected cells in response to MCP-1. Mean6SD of three independent experiments.
doi:10.1371/journal.pone.0019559.g007
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MIN6 cells were cultured in medium without FBS for 12 h,
then were treated with or without various inhibitors for 1 h
followed by 11.63 nM MCP-1 for another 2 h. The nuclear
proteins were prepared with NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo, Rochford, USA). The protein
concentration was determined using Bradford assay. EMSA was
performed with LightShift Chemiluminescent EMSA kit (Pierce
Chemical Co., Rockford, USA). Briefly, 20 mg nuclear proteins
were pre-incubated with binding buffer for 10 min at 4uC and
then incubated with biotin-labeled AP1 probe for another 20 min
at room temperature. For competition experiments, a 100-fold
excess of unlabelled doubled-stranded AP1 oligonucleotides was
added to the binding reaction. DNA-protein complexes were
analyzed by electrophoresis in 4% polyacrylamide gels. Complexes
were transferred to a nylon membrane (Pierce Chemical Co.,
Rockford, IL, USA) and crosslinked to the membrane using a
hand-held UV lamp equipped with 254 nm bulbs. Migration of
the biotinylated oligonucleotides and their complexes was detected
by chemiluminescence followed by exposure of the membrane to
X-ray films. The oligonucleotide sequences of AP1 probes were:
amylin AP1 probe: 59-AAGAGCTTGAGTCACACAAGA-39 ;
consensus AP1 probe: 59-CGCTTGATGACTCAGCCGGAA-39.
Statistical analysis
Results are expressed as means6SD of at least three
independent experiments. Statistical analysis was performed using
ANOVA for time-course and dose-response, and Student’s t test
for other data.
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